Genmab — Marts 2017
-
96,000,000kr
-
så er der lidt til basserne!
-
jeg har altid været stor tilhænger af JVW, men jeg har altså lidt svært ved at se, hvordan man kan forsvare disse summer. De warrants er jo 30% af 2016s overskud,
-
80.000 aktier er jo i nærheden af 110 millioner kroner for ham
-
og vi snakker om en CEO med 200 ansatte under sig
-
Regarding the warrants:
-
-
- JvdW knows a lot more about the progressing of the different clinical studies then is public incl I/O. I believe he knows exactly what will happen in the comin 12 - 24 months and that is that there will be coming a flow of extremly significant data that will sky rocket the share price, therefore JvdW is certain that all Genmab shareholders will benefit significantly and that's why he believes the current warrant program is fair.
-
- I also believe he knows that a takeover of Genmab is coming within a certain amount of time, say 12 - 24 months. Therefore there is not much time left to further reward Genmabs BoD and employees.
-
- you could argue that they've already been awarded enough. Seen the significant value Genmab is delivering and more importantly is going to deliver in the next 12 - 24 months I have less problems with these practises. It's worlds best performing stock for the last 5 years!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind